| A role for glial cell–derived neurotrophic factor–induced expression by inflammatory cytokines and ret/gfrα1 receptor up-regulation in breast cancer S Esseghir, SK Todd, T Hunt, R Poulsom, I Plaza-Menacho, JS Reis-Filho, ... Cancer Research 67 (24), 11732-11741, 2007 | 186 | 2007 |
| Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance I Plaza-Menacho, A Morandi, D Robertson, S Pancholi, S Drury, ... Oncogene 29 (33), 4648-4657, 2010 | 163 | 2010 |
| Current concepts in RET-related genetics, signaling and therapeutics I Plaza-Menacho, GM Burzynski, JW de Groot, BJL Eggen, RMW Hofstra TRENDS in Genetics 22 (11), 627-636, 2006 | 148 | 2006 |
| GDNF–RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors A Morandi, LA Martin, Q Gao, S Pancholi, A Mackay, D Robertson, ... Cancer research 73 (12), 3783-3795, 2013 | 130 | 2013 |
| Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting I Plaza-Menacho, L Mologni, E Sala, C Gambacorti-Passerini, AI Magee, ... Journal of Biological Chemistry 282 (40), 29230-29240, 2007 | 118 | 2007 |
| Mechanisms of RET signaling in cancer: current and future implications for targeted therapy I Plaza-Menacho, L Mologni, NQ McDonald Cellular signalling 26 (8), 1743-1752, 2014 | 113 | 2014 |
| Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase L Mologni, S Redaelli, A Morandi, I Plaza-Menacho, ... Molecular and cellular endocrinology 377 (1-2), 1-6, 2013 | 109 | 2013 |
| RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line–derived neurotrophic factor IP Menacho, R Koster, AM Van Der Sloot, WJ Quax, J Osinga, ... Cancer Research 65 (5), 1729-1737, 2005 | 107 | 2005 |
| RET in breast cancer: functional and therapeutic implications A Morandi, I Plaza-Menacho, CM Isacke Trends in molecular medicine 17 (3), 149-157, 2011 | 101 | 2011 |
| Ras/ERK1/2-mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos … I Plaza-Menacho, T van der Sluis, H Hollema, O Gimm, CHCM Buys, ... Journal of biological chemistry 282 (9), 6415-6424, 2007 | 88 | 2007 |
| Cyclic di-GMP mediates a histidine kinase/phosphatase switch by noncovalent domain cross-linking BN Dubey, C Lori, S Ozaki, G Fucile, I Plaza-Menacho, U Jenal, ... Science Advances 2 (9), e1600823, 2016 | 85 | 2016 |
| Clinicopathologic assessment of postradiation sarcomas: KIT as a potential treatment target R Komdeur, HJ Hoekstra, WM Molenaar, E Van Den Berg, N Zwart, ... Clinical cancer research 9 (8), 2926-2932, 2003 | 79 | 2003 |
| Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations JWB de Groot, IP Menacho, H Schepers, LJ Drenth-Diephuis, J Osinga, ... Surgery 139 (6), 806-814, 2006 | 76 | 2006 |
| Identifying candidate Hirschsprung disease–associated RET variants GM Burzynski, IM Nolte, A Bronda, KK Bos, J Osinga, IP Menacho, B Twigt, ... The American Journal of Human Genetics 76 (5), 850-858, 2005 | 72 | 2005 |
| Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans I Plaza-Menacho, K Barnouin, K Goodman, RJ Martínez-Torres, A Borg, ... Molecular Cell 53 (5), 738-751, 2014 | 67 | 2014 |
| Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism I Plaza-Menacho, A Morandi, L Mologni, P Boender, ... Journal of Biological Chemistry 286 (19), 17292-17302, 2011 | 62 | 2011 |
| Localizing a putative mutation as the major contributor to the development of sporadic Hirschsprung disease to the RET genomic sequence between the promoter region and exon 2 GM Burzynski, IM Nolte, J Osinga, I Ceccherini, B Twigt, S Maas, A Brooks, ... European journal of human genetics 12 (8), 604-612, 2004 | 59 | 2004 |
| Structure and function of RET in multiple endocrine neoplasia type 2 I Plaza-Menacho Endocrine-related cancer 25 (2), T79-T90, 2018 | 52 | 2018 |
| Hybrid histidine kinase activation by cyclic di-GMP–mediated domain liberation BN Dubey, E Agustoni, R Böhm, A Kaczmarczyk, F Mangia, C von Arx, ... Proceedings of the National Academy of Sciences 117 (2), 1000-1008, 2020 | 33 | 2020 |
| RET functions as a dual-specificity kinase that requires allosteric inputs from juxtamembrane elements I Plaza-Menacho, K Barnouin, R Barry, A Borg, M Orme, R Chauhan, ... Cell Reports 17 (12), 3319-3332, 2016 | 31 | 2016 |
